Reframing small cell lung cancer: therapeutic lessons from hematologic malignancies

1

Small cell lung cancer (SCLC) is highly aggressive, with rapid growth and poor long-term survival despite initial treatment sensitivity.
2

SCLC shares biological features with hematologic malignancies, including lineage state dependence and adaptive resistance mechanisms.
3

Dynamic transitions between neuroendocrine and non-neuroendocrine states in SCLC affect antigen expression and treatment vulnerability.
4

Emerging therapies targeting specific antigens and epigenetic regulators show promise but face challenges from tumor heterogeneity and microenvironmental barriers.
5

Durable treatment for SCLC will likely require biomarker-driven combination strategies that address tumor plasticity and metabolic adaptations.

Frontiers In Oncology

1